Santaris Pharma has appointed Arthur Levin, its chief development officer, as president of its new California-based subsidiary.
Levin previously served as vice president of drug development at Isis Pharmaceuticals. He holds a PhD in toxicology from the University of Rochester School of Medicine and Dentistry.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
